Recent Updates
Recently added Catalysts
CORT Positive Sentiment

ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer

Key Takeaway: Corcept Therapeutics announced the publication of a case report in ESMO Rare Cancers. The report details an approximately eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer. This finding highlights the potential long-term efficacy of the treatment combination.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eight-year response noted in a patient
  • Publication in a peer-reviewed journal
  • Combination therapy shows promising results

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+49%
120-day peak, hindsight
Typical move
11.3%
average across 7 past catalysts
Lead asset
Miricorilant Treatment A
Phase 1 · Undisclosed

Full Press Release Details

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced publication of a peer-reviewed case report in ESMO Rare Cancers, regarding an approximately eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulva

Frequently Asked Questions

What is relacorilant?

Relacorilant is a medication developed to modulate cortisol effects.

What was the duration of the response in the case report?

The response lasted approximately eight years.

Where was the case report published?

It was published in ESMO Rare Cancers.

What type of cancer was studied in the report?

The report studied metastatic vulvar cancer.

Last updated: Nov 16, 2026